Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Maintenance in mCRC (TIME)
NCT02404935Phase 2Completed
- Sponsor
- Unicancer
- Start
- Nov 2013
- Primary completion
- Nov 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in colorectal cancer (metastatic) (mCRC), sponsored by Unicancer. Started Nov 2013; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02404935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404935.